It wont hurt, but the only thing that is going to make this fly is an out-licensing deal.
Duthy has repeatedly spruiked NEU's commercial strategy for Daybue which was the same. Fully support this commercial direction (or M&A or equity) in the US, EU and Asian markets.
Their decision to retain 100% commercial ownership of NTI164 assets in Australia is one with some risk and cost presumably - but may be shortened by the provisional registration pathway process.
Ann: US FDA orphan drug designation requested for Rett Syndrome, page-6
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
-0.001(1.85%) |
Mkt cap ! $54.83M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.5¢ | 5.3¢ | $33.62K | 629.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 3755572 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 120107 | 3 |
View Market Depth
| Last trade - 14.27pm 08/11/2024 (20 minute delay) ? |
| NTI (ASX) Chart |